Myeloma Paper of the Day, July 11th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Nice review of novel approaches to managing patients with relapsed and refractory Waldenström macroglobulinemia showing many options, though few FDA approvals or comparative effectiveness studies.”
Source: Robert Orlowski/X
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
Authors: Karan L. Chohan and Prashant Kapoor.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
